[1]吕艳杭,吴姗姗,王振常,等.柔肝化纤颗粒治疗乙肝肝硬化腹水的临床疗效及对肝纤维化、氧化应激水平的影响[J].西部中医药,2021,34(03):19-24.[doi:10.12174/j.issn.2096-9600.2021.03.05]
　LYU Yanhang,WU Shanshan,WANG Zhenchang,et al.Curative Effects of Rougan Huaxian Granules in Treating Ascites of Hepatitis B Cirrhosis and Its Influence on the Levels of Oxidative Stress and Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2021,34(03):19-24.[doi:10.12174/j.issn.2096-9600.2021.03.05]
点击复制

柔肝化纤颗粒治疗乙肝肝硬化腹水的临床疗效及对肝纤维化、氧化应激水平的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年03期
页码:
19-24
栏目:
临床论著
出版日期:
2021-03-15

文章信息/Info

Title:
Curative Effects of Rougan Huaxian Granules in Treating Ascites of Hepatitis B Cirrhosis and Its Influence on the Levels of Oxidative Stress and Liver Fibrosis
作者:
吕艳杭1, 吴姗姗1, 王振常2, 温智稀2, 符燕青1, 苏晓文1, 农小欣1, 段桂姣1
1.广西中医药大学研究生学院 广西 南宁 530222
2.广西国际壮医医院脾胃肝病科
Author(s):
LYU Yanhang1, WU Shanshan1, WANG Zhenchang2, WEN Zhixi2, FU Yanqing1, SU Xiaowen1, NONG Xiaoxin1, DUAN Guijiao1
1.Graduate School, Guangxi University of Chinese Medicine, Nanning 530222, China
2.Department of Spleen, Stomach and Liver Disease, Guangxi International Zhuang Medicine Hospital
关键词:
乙肝肝硬化; 腹水; 氧化应激; 肝纤维化; 柔肝化纤颗粒
Keywords:
hepatitis B cirrhosis; ascites; oxidative stress; liver fibrosis; granules
分类号:
R575.2
DOI:
10.12174/j.issn.2096-9600.2021.03.05
摘要:
目的观察柔肝化纤颗粒治疗乙肝肝硬化的临床疗效，探讨其对肝纤维化、氧化应激水平的影响。 方法将乙肝肝硬化腹水患者60例采用随机数字表法分为两组各30例。对照组采用西医常规治疗，治疗组在对照组治疗的基础上加用柔肝化纤颗粒。治疗1个月后观察两组患者治疗前后中医证候、肝功能、体质量、腹围、24 h尿量、电解质变化情况。比较两组患者临床疗效、肝纤维化［透明质酸（hyaluronicacid，HA）、层黏连蛋白（laminin，LN）、Ⅲ型胶原（procollagen type Ⅲ，PCⅢ）、Ⅳ型胶原（collagen type Ⅳ，Ⅳ-C）]程度及氧化应激［超氧化物歧化酶（superoxide dismutase，SOD）、谷胱甘肽过氧化物酶（glutathione peroxidase，GSH-Px）、丙二醛(malondialdehyde，MDA）］水平。 结果1）治疗后两组患者中医证候积分、肝功能［天冬氨酸氨基转移酶（aspartate transaminase，AST）、谷丙转氨酶（alanine transaminase，ALT）、总胆红素（total bilirubin，TBIL）、白蛋白（albumin，ALB）］指标水平较治疗前下降（P＜0.05），治疗组低于对照组（P＜0.05）；2）治疗后两组患者体质量较治疗前减轻，腹围较治疗前减小（P＜0.05），24 h尿量较治疗前增多（P＜0.05），治疗组变化更明显（P＜0.05）；3）电解质紊乱发生率治疗组为23.3%（7/30），低于对照组的63.3%（19/30）（P＜0.05）；4）治疗后两组肝纤维化（HA、LN、PCⅢ、IV-C）较治疗前减轻，氧化应激（SOD、GSH-Px、MDA）水平较治疗前下降（P＜0.05），治疗组低于对照组（P＜0.05）；5）总有效率治疗组为93.3%（28/30），高于对照组的76.7%（23/30）（P＜0.05）。 结论西医常规联合柔肝化纤颗粒有助于乙肝肝硬化腹水患者消腹水、利尿，能提高患者临床疗效及生存质量，降低肝纤维化程度及氧化应激水平。
Abstract:
ObjectiveTo observe therapeutic effects of Rougan Huaxian granules in the treatment of hepatitis B cirrhosis and its influence on the levels of liver fibrosis and oxidative stress. MethodsSixty patients were separated into two groups using random number table method. The control group adopted conventional therapy of Western medicine, and the treatment group took Rougan Huaxian granules based on conventional therapy of Western medicine. After treating for one month, to observe TCM syndrome, liver function, body mass, abdominal circumference, 24-hour urine volume and electrolyte of the patients in both groups before and after treating. To compare clinical effects, the degrees of liver fibrosis (HA, LN, PCⅢ and IV-C), and the levels of oxidative stress (SOD, GSH-Px and MDA) between both groups. Results1)After treating, TCM syndrome integrals, liver function (AST, ALT, ALB and TBIL) of both groups lowered compared with these before treating (P<0.05), the treatment group was lower than the control group (P<0.05); 2)After treating, body mass and abdominal circumference of the patients in both groups lowered than before treating (P<0.05), 24-hour urine volume increased than before treating (P<0.05), the changes of the treatment group were more notable (P<0.05); 3)The incidence of electrolyte disorder of the treatment group was 23.3%(7/30), lower than 63.3%(19/30) of the control group (P<0.05); 4) After treating, the degrees of liver fibrosis (HA, LN, PCⅢ and IV-C), and the levels of oxidative stress (SOD, GSH-Px and MDA) lowered in both groups compared with these before treating (P<0.05), the treatment group was lower than the control group (P<0.05); 5) Total effective rate of the treatment group was 93.3%(28/30), higher than 76.7%(23/30) of the control group (P<0.05). ConclusionConventional therapy of Western medicine and Rougan Huaxian granules could eliminate ascites and promote diuresis, raise clinical effects and quality of life, decrease the levels of liver fibrosis and the levels of oxidative stress.

相似文献/References:

[1]谷雨.刘沈林教授运用健脾化瘀法治疗癌性腹水验案举隅[J].西部中医药,2014,27(12):31.
[2]杨惠敏,蒋春彦.软肝汤联合阿德福韦酯治疗代偿期乙肝肝硬化42例[J].西部中医药,2017,30(12):82.
　YANG Huimin,JIANG Chunyan.Treating 42 Cases of Hepatitis B Cirrhosis at Compensatory Phase by Liver-softening Decoction Combined with Adefovir Dipivoxil[J].Western Journal of Traditional Chinese Medicine,2017,30(03):82.
[3]徐婷婷,安振涛,李慧,等.肝硬化腹水证治分布及脐敷疗法用药规律文献研究[J].西部中医药,2021,34(06):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]
　XU Tingting,AN Zhentao,LI Hui,et al.Literature Study on the Distribution of Syndrome Differentiation and Treatment of Cirrhosis Ascites and Medication Rules of Umbilical Compressing Therapy[J].Western Journal of Traditional Chinese Medicine,2021,34(03):85.[doi:10.12174/j.issn.2096-9600.2021.06.20]

备注/Memo

备注/Memo:
吕艳杭（1994—），女，在读硕士研究生。研究方向：肝纤维化、肝硬化的中西医结合基础与临床研究。
更新日期/Last Update: 2021-03-05